Evidence map›Paper›PMID 36793594›Full record

ArticleFrontiers in oncology2023

MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicing.

Tamara Vital, Aminah Wali, Kyle V Butler, Yan Xiong, Joseph P Foster, Shelsa S Marcel, Andrew W McFadden, Valerie U Nguyen, Benton M Bailey, Kelsey N Lamb and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tamara VitalCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Aminah WaliCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Kyle V ButlerMount Sinai Center for Therapeutics Discovery, Department of Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Yan XiongMount Sinai Center for Therapeutics Discovery, Department of Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Joseph P FosterDepartment of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Shelsa S MarcelDepartment of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Andrew W McFaddenLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Valerie U NguyenLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Benton M BaileyLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Kelsey N LambCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Lindsey I JamesLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Stephen V FryeLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Amber L MoselyIndiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States.
Jian JinMount Sinai Center for Therapeutics Discovery, Department of Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Samantha G PattendenLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Ian J DavisDepartment of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill · USIcahn School of Medicine at Mount Sinai · USIndiana University School of Medicine

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
UNC Initiative for Maximizing Student DevelopmentR25GM055336 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN, KASH, THOMAS L. · 1996 to 2023
$12.1M
CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0M
UNC Predoc Training Progr in Bioinformatics/Comp BiologyT32GM067553 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ELSTON, TIMOTHY C · 2005 to 2019
$2.5M
Chromatin organization and transcription factor targeting in cancerR01CA166447 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIS, IAN J · 2012 to 2016
$1.6M
The application of Enhanced Cavitation to enable DNA and Chromatin Extraction from Archived TissuesR33CA206939 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIS, IAN J, DAYTON, PAUL A · 2017 to 2019
$1.1M
Targeting EWS-FLI1 protein stability as therapeutic strategy for Ewing sarcomaR21CA234979 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIS, IAN J, LIU, PENGDA · 2019 to 2020
$372k
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA166447NCI NIH HHS R21 CA234979NCI NIH HHS R33 CA206939NCI NIH HHS T32 CA071341NIGMS NIH HHS R25 GM055336NIGMS NIH HHS T32 GM067553
6 · The paper itself

Abstract

Ewing sarcoma is a cancer of children and young adults characterized by the critical translocation-associated fusion oncoprotein EWSR1::FLI1. EWSR1::FLI1 targets characteristic genetic loci where it mediates aberrant chromatin and the establishment of

Indexed as

chromatindrug discoveryEwing sarcoma (ES)RNA-binding proteinsRNA-processingSWI/SNF (BAF) complex

Identifiers

PMID36793594
PMCPMC9924231
OpenAlexW4318483337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.